Changing Cancer care using Artificial Intelligence

Made by leveraging multi-omic data, biomarker data, to develop predictive models of response to immuno-oncologic therapy in lung cancer, renal cancers and melanoma.

By leveraging novel AI-driven immuno-oncology markers, we will be able to increase the certainty of which patients will respond to treatment

Our advantages include validation of the predictive tools on datasets relevant to the UK population, focus on immune checkpoint inhibitors which is the fastest growing market segment in cancer immunotherapy, utlising a spectrum of data including histopathology, and leveraging existing collaborations with UK institutions known for big data AI analytics in health.